Search Result

Pathways Recommended:	Antibody-drug Conjugate/ADC Related

Results for "

Antitumor drugs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibody-Drug Conjugates (ADCs) (16) Drug Intermediate (2) Drug-Linker Conjugates for ADC (18) Peptide-Drug Conjugates (PDCs) (2) Radionuclide-Drug Conjugates (RDCs) (2) ADC Antibody (6) ADC Cytotoxin (13) ADC Linker (1) Amino Acid Derivatives (1) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (3) Antifolate (1) Apoptosis (22) Autophagy (7) Bacterial (5) Bcl-2 Family (2) Biochemical Assay Reagents (2) c-Met/HGFR (1) Carboxylesterase (CES) (2) Caspase (1) CD22 (1) CD276/B7-H3 (1) CDK (2) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (4) DNA/RNA Synthesis (2) EGFR (9) Endogenous Metabolite (5) ERK (1) Eukaryotic Initiation Factor (eIF) (1) Ferroptosis (1) Folate Receptor (FR) (1) Fungal (1) Glutathione S-transferase (1) HBV (1) HCV (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HIV (4) HSP (1) Integrin (1) Interleukin Related (1) Isotope-Labeled Compounds (1) JNK (1) Liposome (8) Malate Dehydrogenase (MDH) (1) MDM-2/p53 (3) Microtubule/Tubulin (24) Mitochondrial Metabolism (2) MNK (1) mTOR (1) NF-κB (2) P-glycoprotein (4) p38 MAPK (3) Parasite (3) PD-1/PD-L1 (2) Phosphodiesterase (PDE) (1) PI3K (1) PPAR (1) PROTACs (1) Reactive Oxygen Species (ROS) (2) Reverse Transcriptase (1) SARS-CoV (3) Sigma Receptor (1) Somatostatin Receptor (2) Src (1) STAT (2) TAM Receptor (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) Topoisomerase (7) Trk Receptor (1) TROP2 (2) TRP Channel (1) Tyrosinase (1) UGT (2)
By Research Areas:	Cancer (112) Cardiovascular Disease (1) Infection (13) Inflammation/Immunology (9) Metabolic Disease (2) Neurological Disease (3)

By Targets:

Antibody-Drug Conjugates (ADCs) (16)

Drug Intermediate (2)

Drug-Linker Conjugates for ADC (18)

Peptide-Drug Conjugates (PDCs) (2)

Radionuclide-Drug Conjugates (RDCs) (2)

ADC Antibody (6)

ADC Cytotoxin (13)

ADC Linker (1)

Amino Acid Derivatives (1)

Anaplastic lymphoma kinase (ALK) (1)

Antibiotic (3)

Antifolate (1)

Apoptosis (22)

Autophagy (7)

Bacterial (5)

Bcl-2 Family (2)

Biochemical Assay Reagents (2)

c-Met/HGFR (1)

Carboxylesterase (CES) (2)

Caspase (1)

CD22 (1)

CD276/B7-H3 (1)

CDK (2)

Cyclin G-associated Kinase (GAK) (1)

Cytochrome P450 (1)

DNA Alkylator/Crosslinker (4)

DNA/RNA Synthesis (2)

EGFR (9)

Endogenous Metabolite (5)

ERK (1)

Eukaryotic Initiation Factor (eIF) (1)

Ferroptosis (1)

Folate Receptor (FR) (1)

Fungal (1)

Glutathione S-transferase (1)

HBV (1)

HCV (1)

HDAC (1)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (1)

HIV (4)

HSP (1)

Integrin (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

JNK (1)

Liposome (8)

Malate Dehydrogenase (MDH) (1)

MDM-2/p53 (3)

Microtubule/Tubulin (24)

Mitochondrial Metabolism (2)

MNK (1)

mTOR (1)

NF-κB (2)

P-glycoprotein (4)

p38 MAPK (3)

Parasite (3)

PD-1/PD-L1 (2)

Phosphodiesterase (PDE) (1)

PI3K (1)

PPAR (1)

PROTACs (1)

Reactive Oxygen Species (ROS) (2)

Reverse Transcriptase (1)

SARS-CoV (3)

Sigma Receptor (1)

Somatostatin Receptor (2)

Src (1)

STAT (2)

TAM Receptor (1)

TNF Receptor (2)

Toll-like Receptor (TLR) (1)

Topoisomerase (7)

Trk Receptor (1)

TROP2 (2)

TRP Channel (1)

Tyrosinase (1)

UGT (2)

By Research Areas:

Cancer (112)

Cardiovascular Disease (1)

Infection (13)

Inflammation/Immunology (9)

Metabolic Disease (2)

Neurological Disease (3)

116

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Drug Metabolite Drug Intermediate Drug Isomer Drug Derivative Antibody-Drug Conjugates (ADCs) Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Drug-Linker Conjugates for ADC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P10128

GE11 1 Publications Verification	Biochemical Assay Reagents	Inflammation/Immunology
GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study .

HY-168489

OBI-992 drug-linker	Drug-Linker Conjugates for ADC	Cancer
OBI-992 drug-linker is a drug-linker conjugate composed of a TOP I inhibitor Exatecan (HY-13631) and a linker. OBI-992 drug-linker exhibits antitumor property in mouse models and can be used for synthesis of ADC OBI-992 .

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a	Antibody-Drug Conjugates (ADCs)	Cancer
Ifinatamab deruxtecan (DS-7300a) is an ADC that binds an anti-B7-H3 antibody to the DNA topoisomerase I inhibitory anti-tumor drug DXd. Ifinatamab deruxtecan has antitumor activity .

HY-W011556

N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate TCFH	Biochemical Assay Reagents	Others
N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate is a kind of biological coupling reagent, can be used for antitumor drugs sulphur alkali before medicine research .

HY-N2493

Lawsone 1 Publications Verification	Fungal Apoptosis	Infection Cancer
Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Amino Acid Derivatives	Others Cancer
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an *antibody-drug* conjugate (ADC) (Antibody-Drug Conjugates (ADCs)*) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor* activities .

HY-176455

ADC-5 drug-linker	Drug-Linker Conjugates for ADC	Cancer
ADC-5 drug-linker (Compound linker-payload 5) is a drug-linker conjugate for ADC with potent anti-tumor activity. ADC-5 drug-linker can be used to synthesize NLRP3 agonist 3 (HY-176452) .

HY-162462

Antitumor agent-151	Apoptosis	Cancer
Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC₅₀ = 0.79 μM) and antitumor activity in vitro (IC₅₀ = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis .

HY-156411

NR-NO2	Bacterial	Cancer
NR-NO2 is a potential drug with targeted release and imaging-based guidance in *antitumor* research. NR-NO2 has an *anti-bacterial* effect .

HY-101150

DGN462	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .

HY-171508

Mal-PNU-159682	Drug-Linker Conjugates for ADC	Cancer
Mal-PNU-159682 is a Drug-Linker Conjugates for ADC, composes of ADC linker (maleimide) and ADC cytotoxin PNU-159682 (HY-16700), and has anti-tumor activity .

HY-19474

Maytansinol Ansamitocin P-0	Microtubule/Tubulin ADC Cytotoxin Apoptosis	Cancer
Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research .

HY-141602

Pinatuzumab vedotin anti-CD22-vc-MMAE; DCDT2980S	Antibody-Drug Conjugates (ADCs) CD22 Microtubule/Tubulin	Cancer
Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities .

HY-126643

Wedeloside	Mitochondrial Metabolism	Others Cancer
Wedeloside is a diterpenoid amino glycoside isolated from the plant Wedelia asperrima. Wedeloside is capable of inhibiting ADP-stimulated respiration in mitochondria and possesses potential anti-tumor activity. Wedeloside is applicable in drug development and toxicological research .

HY-170865

OncoFAP-GlyPro-MMAF	Drug-Linker Conjugates for ADC	Cancer
OncoFAP-GlyPro-MMAF is a Drug-Linker Conjugate for ADC with potent antitumor activity. OncoFAP-GlyPro-MMAF consists of Monomethylauristatin F (HY-15579) and a linker. OncoFAP-GlyPro-MMAF can be used for synthesis of ADCs .

HY-141598

Datopotamab deruxtecan DS-1062; Dato-DXd	TROP2 Antibody-Drug Conjugates (ADCs) Topoisomerase	Cancer
Datopotamab deruxtecan (DS-1062; Dato-DXd) is a *trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug* conjugate (ADC)*. Datopotamab deruxtecan has a potent antitumor* activity .

HY-127079

Epothilone F	Microtubule/Tubulin	Cancer
Epothilone F is a Microtubule/Tubulin-stabilizing agent with anti-tumor activity. Epothilone F inhibits the proliferation of breast cancer cells, non-small cell lung cancer cells, drug-resistant ovarian cancer cells .

HY-171135

Cetuximab MMAE	Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin	Cancer
Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity .

HY-144880

SC209 3-Aminophenyl Hemiasterlin	ADC Cytotoxin Microtubule/Tubulin P-glycoprotein	Cancer
SC209 (3-Aminophenyl Hemiasterlin) is a 3-aminophenyl hemiasterlin derivative that serves as a cytotoxin for ADCs, targeting tubulin. SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. SC209 exhibits antitumor activity and can be used in the synthesis of ADC molecules .

HY-W778423

[Pt(DACH)(OH)2(ox)] Dihydroxy Oxaliplatin-Pt(IV)	Drug Intermediate	Cancer
[Pt(DACH)(OH)2(ox)] is a Oxaliplatin (HY-17371)-based Pt(IV) scaffold. [Pt(DACH)(OH)2(ox)] reacts with N-hydroxysuccinimide (NHS) ester of PPA to yield phorbiplatin. Phorbiplatin is a highly potent Pt(IV) antitumor prodrug .

HY-15579A

MMAF hydrochloride Maximum Cited Publications 8 Publications Verification Monomethylauristatin F hydrochloride	Microtubule/Tubulin ADC Cytotoxin	Cancer
MMAF (Monomethylauristatin F) hydrochloride is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF hydrochloride is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-148128

TAM470	Microtubule/Tubulin ADC Cytotoxin	Cancer
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .

HY-144497

HE-S2	PD-1/PD-L1 Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC	Infection Cancer
HE-S2 is an antibody-drug conjugate triggering a potent antitumor immune response. HE-S2 acts by blocking the PD-1/PD-L1 interaction and activating the Toll-like receptor 7/8 (TLR7/8) signaling pathway. HE-S2 has remarkable antitumor activity .

HY-B0067B

(R)-Amrubicin (R)-SM-5887	Topoisomerase	Cancer
(R)-Amrubicin ((R)-SM-5887) is an anthracycline that effectively treats lung cancer by intercalating into DNA and inhibiting topoisomerase II activity, which consequently hampers DNA replication as well as RNA and protein synthesis, leading to cell growth inhibition and apoptosis. This compound exhibits superior anti-tumor efficacy compared to traditional anthracycline drugs while lacking the cumulative cardiac toxicity typically associated with this drug class.

HY-13554

Annamycin	Antibiotic	Infection Cancer
Annamycin is an antibiotic, that has high affinity for lipid membranes and can bypass the multidrug resistance protein-1 (MDR-1 ) mechanism of cellular drug resistance. Annamycin exhibits antitumor efficacy in multilamellar vesicles against solid tumor .

HY-15579B

MMAF sodium Maximum Cited Publications 8 Publications Verification Monomethylauristatin F sodium	Microtubule/Tubulin ADC Cytotoxin	Cancer
MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15579

MMAF Maximum Cited Publications 8 Publications Verification Monomethylauristatin F	Microtubule/Tubulin ADC Cytotoxin	Cancer
MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-164500

MC3629	Apoptosis Histone Methyltransferase	Cancer
MC3629 is an inhibitor of histone methyltransferase (EZH2) with anti-tumor activity. MC3629 inhibits SHH MB cancer cell proliferation and self-renewal and induces apoptosis. MC3629 can be used to study drug resistance in tumor aggressiveness .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted *antibody-drug* conjugate (ADC)*. ADCT-601 has anti-tumor* activity .

HY-123891

NS-062	EGFR	Cancer
NS-062 is an orally active, irreversible targeted covalent inhibitor for EGFR, and exhibits antiproliferative efficacy in drug-resistant double mutated H1975 cell with an IC₅₀ of 0.19 μM. NS-062 exhibits antitumor efficacy in mouse H1975 xenograft model .

HY-P9985

Disitamab vedotin 2 Publications Verification RC48	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity .

HY-P10742

CBX-12	Peptide-Drug Conjugates (PDCs) Topoisomerase	Cancer
CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan (HY-13631) .

HY-P9921

Trastuzumab emtansine 2 Publications Verification Ado-Trastuzumab emtansine; PRO132365; T-DM 1	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-P9921A

Trastuzumab emtansine (solution) 2 Publications Verification Ado-Trastuzumab emtansine (solution) ; PRO132365 (solution) ; T-DM 1 (solution)	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer .

HY-19474R

Maytansinol (Standard) Ansamitocin P-0 (Standard)	Microtubule/Tubulin ADC Cytotoxin Apoptosis	Cancer
Maytansinol (Standard) is the analytical standard of Maytansinol. This product is intended for research and analytical applications. Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research[1][2].

HY-P99045

Sacituzumab	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-173182

Antitumor agent-200	Microtubule/Tubulin P-glycoprotein	Cancer
Antitumor agent-200 (Compound 2g) is a microtubule synthesis inhibitor. By binding to the colchicine site of tubulin, it causes G2/M cell cycle arrest and generates reactive oxygen species (ROS). Antitumor agent-200 exhibits significant inhibitory activity against MCF7/ADR and KBV200 cell lines with overexpression of P-glycoprotein (P-gp), with drug resistance indices (DRI) of 0.83 and 0.58 respectively. In the MCF-7 xenograft model, Antitumor agent-200 (25 mg/kg, intraperitoneal injection) can achieve a tumor growth inhibition rate of 57.2%. Antitumor agent-200 can be used in the research of the anti-cancer field .

HY-P10239

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-145989S

Aminobenzenesulfonic auristatin E-d8	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Aminobenzenesulfonic auristatin E-d₈ is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .

HY-172497

DSPE-PEG2000-CREKA	Liposome	Cancer
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-CREKA	Liposome	Cancer
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-W783643

Hericenone B	Integrin	Cardiovascular Disease Cancer
Hericenone B is a compound that can be isolated and extracted from Hericium erinaceus. Hericenone B exhibits certain cytotoxicity against Hela cells. Hericenone B can specifically inhibit collagen-induced platelet aggregation. Hericenone B can be used in the research of anti-tumor and antithrombotic drugs .

HY-172498

DSPE-PEG5000-CREKA	Liposome	Cancer
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-129880

Desacetylvinblastine hydrazide Deacetylvinblastine hydrazide; DAVLBH	Microtubule/Tubulin	Cancer
Desacetylvinblastine hydrazide (Deacetylvinblastine hydrazide; DAVLBH) is an active component of EC145, a folate-targeted drug conjugate. Desacetylvinblastine hydrazide interferes with the formation of the mitotic spindle, and thus inhibits cell division and leads to cell death. Desacetylvinblastine hydrazide exhibits antitumor activity against folate receptor (FR)-positive tumor .

HY-172497A

DSPE-PEG3400-CREKA	Liposome	Cancer
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

HY-P10239A

Tyr3-Octreotate acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-147021

MC-Val-D-Cit-PAB-PNP	ADC Linker	Cancer
MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). MC-Val-D-Cit-PAB-PNP contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to antitumor compounds.

HY-112786

MC-Val-Cit-PAB-MMAF 2 Publications Verification Vc-MMAF	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .

HY-W125014

Octahydrocyclopenta[c]pyrrole	Drug Intermediate
Octahydrocyclopenta[c]pyrrole is a multifunctional organic compound with significant biological activity and compound development potential. Octahydrocyclopenta[c]pyrrole has shown good application prospects in the fields of anti-inflammatory, anti-tumor and neuroprotection. The unique structure-activity relationship of Octahydrocyclopenta[c]pyrrole provides new ideas for the design of new drugs.

Cat. No.	Product Name

HY-L107

Anti-Cancer Natural Product Library

1,800 compounds

With features of enormous scaffold diversity and structural complexity, natural products (NPs) are the main sources of lead compounds and new drugs and play a highly significant role in the drug discovery and development process, especially for cancer and infectious diseases. A large number of natural products have been proven to have potential anti-tumor effects, mainly from plants, animals, Marine organisms and microorganisms. At present, derived than 60% of anti-tumor drugs come from natural sources, and they are widely used in breast, prostate and colon cancers.

MCE offers a unique collection of 1,800 natural products with validated anti-cancer activity. MCE anti-cancer natural product library is a useful tool for anti-tumor drugs screening and other related research.

HY-L080

Targeted Therapy Drug Library

105 compounds

Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer.

There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases.

MCE carefully collects a unique of 105 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

HY-L084

Microbial Metabolite Library

885 compounds

Nature has been a source of medicinal products for millennia, with many useful active substances developed from plant sources. In the 20th century, the discovery of the penicillin was the starting point for drug discovery from microbial sources. Microorganisms， which have been considered to be a rich source of unique bioactive compounds, play an important role in the development of the chemistry of natural products and medical therapy. Microbial metabolites have proved to be affective antimicrobial agents, anti-tumor agents, enzyme inhibitors, anti-inflammatory agents, etc. Today, many microbial-originated antibiotics are available in the mark, and a large number of bioactive metabolites are used in medicine.

MCE provides a unique collection of 885 microbial metabolites, which is an important source of lead compounds and can be used for drug discovery.

HY-L110

Cyclic Peptide Library

91 compounds

Cyclic peptides are polypeptide chains taking cyclic ring structure, which exhibit diverse biological activities, such as antibacterial activity, immunosuppressive activity and anti-tumor activity. Cyclic peptides, with the features of good binding affinity, target selectivity and low toxicity, show great success as therapeutics. Multiple cyclic peptides are currently in clinical use, for examples, gramicidin and tyrocidine with bactericidal activity, cyclosporin A with immunosuppressive activity, and vancomycin with antibacterial activity. Furthermore, cyclic peptides usually have the sufficient size and a balanced conformational flexibility/rigidity for binding to flat protein-protein interaction (PPI) interfaces, which have potential to develop PPI drugs.

MCE offers a unique collection of 91 cyclic peptides, all of which have good bioactivities. MCE Cyclic Peptide Library is a powerful tool for drug discovery and PPI inhibitor screening.

Cat. No.	Product Name	Type

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Fluorescent Dye
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Fluorescent Dye
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

Cat. No.	Product Name	Type

HY-W011556

N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate TCFH	Biochemical Assay Reagents
N,N,N',N'-Tetramethylchloroformamidinium hexafluorophosphate is a kind of biological coupling reagent, can be used for antitumor drugs sulphur alkali before medicine research .

HY-172497

DSPE-PEG2000-CREKA	Drug Delivery
DSPE-PEG2000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG2000-CREKA can be used for drug delivery .

HY-172496

DSPE-PEG1000-CREKA	Drug Delivery
DSPE-PEG1000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG1000-CREKA can be used for drug delivery .

HY-172498

DSPE-PEG5000-CREKA	Drug Delivery
DSPE-PEG5000-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG5000-CREKA can be used for drug delivery .

HY-172497A

DSPE-PEG3400-CREKA	Drug Delivery
DSPE-PEG3400-CREKA is a PEG compound which composed of DSPE and a fibrin-targeting peptide (CREKA). CREKA peptide can be used to target tumor cells and tumor vasculature, exhibiting antitumor activity. DSPE-PEG3400-CREKA can be used for drug delivery .

HY-15579BG

MMAF sodium (GMP) Monomethylauristatin F sodium (GMP)	Biochemical Assay Reagents
MMAF sodium GMP is a GMP grade MMAF (sodium) (HY-15579B). MMAF sodium (Monomethylauristatin F sodium) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF sodium (Monomethylauristatin F sodium) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as Vorsetuzumab mafodotin and SGN-CD19A .

HY-15579G

MMAF (GMP) Monomethylauristatin F (GMP)	Biochemical Assay Reagents
MMAF (Monomethylauristatin F) GMP is a GMP grade MMAF (HY-15579). MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A .

HY-172280A

DSPE-PEG2000-octreotide	Drug Delivery
DSPE-PEG21000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG2000-Octreotide can be used for drug delivery .

HY-172280

DSPE-PEG1000-octreotide	Drug Delivery
DSPE-PEG1000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG1000-Octreotide can be used for drug delivery .

HY-172280C

DSPE-PEG3400-octreotide	Drug Delivery
DSPE-PEG3400-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG3400-Octreotide can be used for drug delivery .

HY-172280B

DSPE-PEG5000-octreotide	Drug Delivery
DSPE-PEG5000-Octreotide is a PEG compound which composed of DSPE and a Octreotide (HY-P0036). Octreotide is a somatostatin receptor agonist. Octreotide has antitumor activity, mediates apoptosis and may also be used in disease studies in acromegaly. DSPE-PEG5000-Octreotide can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P10128

GE11 1 Publications Verification	Biochemical Assay Reagents	Inflammation/Immunology
GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study .

HY-P10239A

Tyr3-Octreotate acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10742

CBX-12	Peptide-Drug Conjugates (PDCs) Topoisomerase	Cancer
CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan (HY-13631) .

HY-P10239

Tyr3-Octreotate	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10449

M2 Peptide	Peptides	Cancer
M2 Peptide is a peptide targeting M2-like tumor-associated macrophages (TAMs). M2 Peptide is used to carry drugs or small interfering RNA (siRNA) to promote the repolarization of M2-like macrophages to M1-like macrophages, thereby altering the immunosuppressive state in the tumor microenvironment and enhancing the anti-tumor immune response. M2 Peptide can be used to study the effect of macrophage polarization and how this polarization change affects tumor growth and metastasis .

HY-P10762

CBP-1008 LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
CBP-1008 is a dual-ligand *peptide*-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

Cat. No.	Product Name	Target	Research Area

HY-P3371

Ifinatamab deruxtecan DS-7300a; MABX-9001a	Antibody-Drug Conjugates (ADCs)	Cancer
Ifinatamab deruxtecan (DS-7300a) is an ADC that binds an anti-B7-H3 antibody to the DNA topoisomerase I inhibitory anti-tumor drug DXd. Ifinatamab deruxtecan has antitumor activity .

HY-141607

Indatuximab ravtansine BT-062; nBT062-DM4	Antibody-Drug Conjugates (ADCs) Bacterial	Cancer
Indatuximab ravtansine (BT-062) is an *antibody-drug* conjugate (ADC) (Antibody-Drug Conjugates (ADCs)*) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor* activities .

HY-P99733

Mipasetamab	ADC Antibody TAM Receptor	Cancer
Mipasetamab is an IgG1κ antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted *antibody-drug* conjugate (ADC)*. ADCT-601 has anti-tumor* activity .

HY-P99045

Sacituzumab	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-145627

Ozuriftamab vedotin BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Ozuriftamab vedotin (BA3021), an *antibody-drug* conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2)** humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575). Ozuriftamab vedotin has antitumor activities .

HY-141606

Anetumab ravtansine BAY 94-9343	Microtubule/Tubulin Antibody-Drug Conjugates (ADCs)	Cancer
Anetumab ravtansine (BAY 94-9343) is a selective and highly potent *antibody-drug* conjugate (ADC) to target maytansinoid tubulin*. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor* efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .

HY-P99101

Vobramitamab AEX-4089	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P99151

Brentuximab	ADC Antibody TNF Receptor	Cancer
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC₅₀ of 10 nM against human CD30+ cancer cells .

HY-P99740

Mirzotamab	CD276/B7-H3 ADC Antibody	Cancer
Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC) .

HY-P99612

Farletuzumab ecteribulin MORAb-202	Antibody-Drug Conjugates (ADCs)	Cancer
Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.

HY-P991294

MGTA-117 Antibody	ADC Antibody	Cancer
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy .

HY-P99974

Nab-Paclitaxel 1 Publications Verification Nanoparticle albumin-bound Paclitaxel; Nanoparticle albumin-bound ABI-007	Microtubule/Tubulin Apoptosis Autophagy	Cancer
Nab-Paclitaxel (Nanoparticle albumin-bound Paclitaxel) is an albumin-bound nanoparticle formulation of Paclitaxel (HY-B0015). Nab-Paclitaxel is composed of albumin and the active pharmaceutical ingredient Paclitaxel, in which human albumin is used as an excipient to disperse and stabilize particles and carry the main drug. Nab-Paclitaxel is a solvent-free taxane with higher response rates and improved tolerability. Nab-Paclitaxel displays less toxicity and greater antitumor activity. Nab-Paclitaxel is more readily available for tumor cell uptake in three rhabdomyosarcoma, seven neuroblastoma cell lines, and one ostersarcoma cell line Nab-Paclitaxel can be studied in cancer research for example breast cancer and pediatric solid tumors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2493

Lawsone 1 Publications Verification	Infection Quinones Structural Classification Lawsonia inermis L. Lythraceae Classification of Application Fields Source classification Plants Naphthalene Quinones Disease Research Fields	Fungal Apoptosis
Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research .

HY-113003

H-γ-Glu-Gln-OH γ-Glutamylglutamine; γ-Glu-Gln	Structural Classification Animals Classification of Application Fields Ketones, Aldehydes, Acids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Amino Acid Derivatives
H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .

HY-19474

Maytansinol Ansamitocin P-0	Alkaloids Microorganisms Other Alkaloids Source classification Disease Research Fields Cancer	Microtubule/Tubulin ADC Cytotoxin Apoptosis
Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research .

HY-W012531

2-Hydroxycinnamic acid	Infection Structural Classification Monophenols Cinnamomum cassia (L.) D. Don Classification of Application Fields Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Lauraceae Disease Research Fields	HIV SARS-CoV Endogenous Metabolite Bacterial
2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against *Staphylococcus aureus* and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC₅₀ of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

HY-W012531R

2-Hydroxycinnamic acid (Standard)	Structural Classification Monophenols Cinnamomum cassia (L.) D. Don Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Lauraceae	HIV SARS-CoV Endogenous Metabolite Bacterial
2-Hydroxycinnamic acid (Standard) is the analytical standard of 2-Hydroxycinnamic acid. This product is intended for research and analytical applications. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against *Staphylococcus aureus* and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC₅₀ of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

HY-N0235

Bakuchiol 2 Publications Verification (S)-(+)-Bakuchiol	Structural Classification Monophenols Classification of Application Fields Leguminosae Source classification Phenols Psoralea corylifolia L. Plants Disease Research Fields Cancer	Carboxylesterase (CES) p38 MAPK Autophagy UGT
Bakuchiol is a phytoestrogen that can be obtained from psoralen seeds. Bakuchiol has been proven to be a non-competitive inhibitor of multiple enzymes, including UDP-glucuronosyltransferase 2B7 (UGT2B7) and human carboxylesterase 2 (hCE2) , with IC₅₀s values of 40.9 μM and 7.28 μM, respectively. Bakuchiol exhibits significant research and application potential in areas such as anti-inflammatory , antibacterial , antitumor therapies, as well as drug metabolism regulation.

HY-126643

Wedeloside	Structural Classification Microorganisms Terpenoids Source classification Diterpenoids	Mitochondrial Metabolism
Wedeloside is a diterpenoid amino glycoside isolated from the plant Wedelia asperrima. Wedeloside is capable of inhibiting ADP-stimulated respiration in mitochondria and possesses potential anti-tumor activity. Wedeloside is applicable in drug development and toxicological research .

HY-19474R

Maytansinol (Standard) Ansamitocin P-0 (Standard)	Alkaloids Microorganisms Other Alkaloids Source classification	Microtubule/Tubulin ADC Cytotoxin Apoptosis
Maytansinol (Standard) is the analytical standard of Maytansinol. This product is intended for research and analytical applications. Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research[1][2].

HY-W783643

Hericenone B	Structural Classification Monophenols Microorganisms Source classification Phenols	Integrin
Hericenone B is a compound that can be isolated and extracted from Hericium erinaceus. Hericenone B exhibits certain cytotoxicity against Hela cells. Hericenone B can specifically inhibit collagen-induced platelet aggregation. Hericenone B can be used in the research of anti-tumor and antithrombotic drugs .

HY-N0235R

Bakuchiol (Standard)	Structural Classification Monophenols Leguminosae Source classification Phenols Psoralea corylifolia L. Plants	Carboxylesterase (CES) p38 MAPK Autophagy UGT
Bakuchiol (Standard) is the analytical standard of Bakuchiol. This product is intended for research and analytical applications. Bakuchiol is a phytoestrogen that can be obtained from psoralen seeds. Bakuchiol has been proven to be a non-competitive inhibitor of multiple enzymes, including UDP-glucuronosyltransferase 2B7 (UGT2B7) and human carboxylesterase 2 (hCE2) , with IC₅₀s values of 40.9 μM and 7.28 μM, respectively. Bakuchiol exhibits significant research and application potential in areas such as anti-inflammatory , antibacterial , antitumor therapies, as well as drug metabolism regulation.

HY-W050154R

Kojic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Parasite Tyrosinase NF-κB CDK
Kojic acid (Standard) is the analytical standard of Kojic acid. This product is intended for research and analytical applications. Kojic acid is a substance produced by Aspergillus oryzae, with various biological activities including antitumor, insecticidal, antibacterial, antioxidant, and radioprotective effects. Kojic acid exhibits tyrosinase inhibition activity by capturing copper ions that bind to the active site of tyrosinase, preventing its activation. Tyrosinase is a key enzyme in the biosynthesis of melanin, so kojic acid can block melanin production. Additionally, kojic acid shows potential inhibition of NF-κB activity in human keratinocytes, which may also be related to the anti-melanogenic effect induced by kojic acid. Kojic acid is effective when administered orally and can also be absorbed transdermally. Nano-carrier systems prepared with kojic acid demonstrate effective delivery of anticancer drugs. Kojic acid holds promise for research in cancer, infectious diseases, and skin whitening among other fields .

Cat. No.	Product Name	Chemical Structure

HY-145989S

Aminobenzenesulfonic auristatin E-d8
Aminobenzenesulfonic auristatin E-d₈ is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .

HY-W012531S2

2-Hydroxycinnamic acid-d4

2-Hydroxycinnamic acid-d₄ is deuterium labeled 2-Hydroxycinnamic acid. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC₅₀ of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks